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only faces almost insurmountable problems as it
tries to form a new government, it also faces
many serious health issues including sexually
transmitted diseases (STDs).
Surveillance data from the Ukrainian STD
Center from January 1, 1989, through December
31, 1995, were analyzed on the basis of reports
received through 1997. In western Europe, the
incidence of syphilis and gonorrhea declined
from 1980 to 1991 to less than 2% per 100,000
persons for syphilis and less than  20% per
100,000 persons for gonorrhea. However, in
Ukraine, since 1989, the notification rate of
syphilis has skyrocketedfrom 5 per 100,000
persons in 1990 to 170 in 1995. In some regions,
this rate exceeds 220 cases per 100,000 persons.
Moreover, cases among children younger than
14 years of age are also increasing. In 1995, the
syphilis rate for persons older than 30 years of
age was 170 per 100,000; 600 per 100,000 girls
younger than 15 years of age; and 1,550 to 2,000
per 100,000 girls 15 to 16 years of age. The large
number of girls with the disease is in part due to
teenage prostitution (1).
Most syphilis and gonorrhea cases are
attributed to sexual transmission. Explanations
of this phenomenon include the rapid growth of
the sex industry, increasing numbers of
homeless persons and refugees in Ukrainian
cities, poor diagnostic facilities, punitive legisla-
tion that reduces the likelihood of going to
treatment services, and limited or inadequate
treatment (2).
The Ukrainian government is reviewing its
arrangements for the control of STDs, including
HIV/AIDS, to identify clear objectives and
priorities. Education and treatment would be
effective in preventing the spread of STDs in
Ukraine, but these measures are inadequately
funded (3). Evaluation and risk reduction are
also great weapons in preventing the spread of
STDs (4). However, the response of the local and
world communities has been inadequate in
stemming a major STD epidemic in Ukraine.
United Nations Childrens Fund (UNICEF)
is developing a long-term program in Ukraine
with a focus on STDs in adolescents and youth.
This comprehensive program will tackle not only
STDs but other related issues, such as HIV and
teenagers reproductive health (5).
Greater coordination of the agencies respon-
sible for STD control in Ukraine will be sought,
together with an expansion of health promotion
and prevention projects for young persons and
groups at high risk (6). An effective strategy for
the control of STDs in Ukraine will, therefore,
need to find ways to modify current programs
and the way they interact to create effective
control interventions.
Dmitry I. Ivanov
University of Alabama at Birmingham, Birmingham,
Alabama, USA
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Yellow Fever Vaccine
To the Editor: Monath et al. (1) outlined existing
facilities for distribution of yellow fever vaccines
in the United States and pointed to difficulties
for prospective vaccinees in remote locations.
Their recommendation that primary health-care
providers be allowed to dispense yellow fever
vaccination merits serious consideration. Accep-
tance of such a strategy in the United States
would inevitably be emulated elsewhere.
Nevertheless, before such a strategy is approved,
vaccine potency should be monitored at
distribution points, and a sample of vaccine
recipients should be examined for vaccine-
induced immune response.
In Nigeria, systematic investigation of
yellow fever vaccine distribution and transporta-
tion to remote locations has found loss in vaccine
potency. Vaccine in storage sites and immuniza-488 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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tion centers in Lagos was fully potent, but
potency in Osun and Oyo was 016 log10 to 0.22
log10 lower than the stipulated level (2).
Furthermore, the titer of two vaccine lots that
had been frozen after reconstitution from their
lyophilized state dropped from the initial 3.15
log10 to 3.53 log10 to zero.
If the United States were to implement an
extended strategy, similar studies of vaccine lots
should be conducted to determine whether every
vaccinee has received a full dose of yellow fever
vaccine. In Illinois during the early 1970s, weak
links in maintenance of refrigeration facilities
and use of outdated vaccines in vials exposed to
the sun for long hours were reported for live
poliovirus vaccines (3). In the Northern
Territory of Australia, examination of 144 vials
of hepatitis B vaccine formulations during
transport to immunization centers showed that
47.5% had been exposed to temperatures of -3°C
or lower (4).
Assays of the potency of yellow fever vaccine,
as well as quantification of vaccine-induced
neutralizing antibody, is a multistep procedure
that relies on inoculation of mice or Vero or
polysaccharide cells (5). The successful take of
yellow fever vaccine can be determined starting
the second postvaccination day by demonstrable
viremia detected by reverse-transcriptase poly-
merase chain reaction and by marked increases
in neopterin, beta2-microglobulin, and circulat-
ing CD8+ cells (6). Alternatively, elevated levels
of tumor necrosis factor and interleukin-1
receptor antagonists on day two after vaccina-
tion (7) could be used to monitor the success of
vaccinations by primary-care providers in
remote areas in the United States (1) and
elsewhere.
During the 1990s, isolation of yellow fever
virus was reported in persons with a nonspecific
febrile illness that did not meet the case
definition of yellow fever (8). Air travel by such
persons to the United States, which has areas
infested by Aedes aegypti, could initiate yellow
fever epidemics; because these travelers would
have a nonspecific febrile illness, they would
escape the existing surveillance network.
In conclusion, introducing yellow fever
immunizations by primary health-care providers
would be ideal, only with a concurrent plan to
monitor vaccine potency at immunization
centers and obtain in vitro evidence of a successful
vaccine take. Such a strategy would blunt yellow
feverassociated deaths, illnesses, and symp-
tomless viral carriage in the community.
Subhash C. Arya
Centre for Logistical Research and Innovation
New Delhi, India
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Yellow Fever Vaccine—Reply to S. Arya
To the Editor:  Dr. Arya correctly points out that
there have been problems with degradation of
live viral vaccines, including yellow fever
vaccines, that have not been properly handled
and stored at the point of use. However, in the
United States and western Europe, yellow fever
vaccines are stabilized and require the same
storage facilities at the point of use as other
vaccines routinely distributed by family physi-
cians and pediatricians. Varicella vaccine (and
even measles vaccine) is less stable than yellow
fever vaccine but is distributed to all registered
physicians in the United States. Since vaccines
and other perishable medicines are typically